Showing results (191-200 of 200) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 200 results.
Indian Journal of Cancer|May 10, 2017
Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry based analysisS Zanwar, A Joshi, V Noronha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancersP Bhargava, J L Marshall, W Dahut, et al.
American Journal of Clinical Pathology|October 12, 2000
Endoscopic mapping and surrogate markers for better surveillance in Barrett esophagus. A study of 700 biopsy specimensP Bhargava, G M Eisen, D A Holterman, et al.
Cancer Chemotherapy and Pharmacology|September 20, 2001
Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancerP Bhargava, J L Marshall, K Fried, et al.
Clinical and Molecular Hepatology|December 31, 2014
Composite liver tumors: a radiologic-pathologic correlationMegha Nayyar, David K Imagawa, Temel Tirkes, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2013
Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinomaM N Fishman, S Srinivas, R J Hauke, et al.
American Industrial Hygiene Association Journal|June 1, 1983
Study of an analytical method for hexavalent chromiumO P Bhargava, H E Bumsted, F I Grunder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 8, 2007
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancerJ A Meyerhardt, K Stuart, C S Fuchs, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 11, 2011
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinomaJ A Chan, L S Blaszkowsky, P C Enzinger, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
Comparative outcomes with low-dose and standard-dose immune checkpoint inhibitors in microsatellite stable advanced gastric/gastroesophageal adenocarcinomaA Ramaswamy, V Shenoy, A Bahl, et al.
Pageof 20